Add Dr Reddy's Laboratories - Target Price Rs.1810 - Kotak

OctoPlus acquisition expected to fill technology gap. The acquisition of OctoPlus will provide Dr. Reddy's with the required formulation capabilities for complex injectables. We expect potential generic launches for long acting injectables beyond FY2014, likely to be limited to fewer players.

We remain positive on the strategy to build capabilities rather than acquire products. In our view, this is likely to deliver longterm value. We expect visibility in the US pipeline to emerge over the next 12 months which will be key trigger for stock performance.

Source : Equity Bulls

Keywords